DC
RARE icon

Davenport & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Davenport & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$651K Buy
19,500
+2,000
+11% +$49.7K ﹤0.01% 909
2026
Q1 		$367K Buy
+17,500
New +$394K ﹤0.01% 1052
2022
Q3 		– Sell
-5,782
Closed -$345K – 1023
2022
Q2 		$345K Buy
5,782
+456
+9% +$28.1K ﹤0.01% 780
2022
Q1 		$387K Buy
5,326
+1,135
+27% +$79K ﹤0.01% 802
2021
Q4 		$352K Buy
4,191
+56
+1% +$4.56K ﹤0.01% 856
2021
Q3 		$373K Buy
4,135
+883
+27% +$79.8K ﹤0.01% 794
2021
Q2 		$310K Buy
+3,252
New +$339K ﹤0.01% 775

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Davenport & Co's RARE Position: Q2 2026 in Review

Davenport & Co increased its Ultragenyx Pharmaceutical (RARE) stake by 11% in Q2 2026, buying an estimated $49.7K and bringing the position to 19,500 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #909.

Davenport & Co first reported a position in RARE in Q2 2021 and has held it in 7 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Davenport & Co held 19,500 shares of Ultragenyx Pharmaceutical worth $651K as of Q2 2026.
  • Davenport & Co bought 2,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $49.7K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #909 holding.
  • Davenport & Co first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and has held it in 7 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.